Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00160160
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : January 30, 2009
Sponsor:
Information provided by:
Solvay Pharmaceuticals

Brief Summary:
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Condition or disease Intervention/treatment Phase
Hypertension Type 2 Diabetes Drug: eprosartan/HCTZ Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 440 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2
Study Start Date : October 2004

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Blood pressure reduction

Secondary Outcome Measures :
  1. Comparison of responder rates


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • essential hypertension,
  • diabetes type 2

Exclusion Criteria:

  • severe cardiovascular disease,
  • grade 3 hypertension,
  • secondary hypertension,
  • abnormal liver enzymes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160160


Locations
Show Show 63 study locations
Sponsors and Collaborators
Solvay Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00160160    
Other Study ID Numbers: S171.3.012
2004-00703-18
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: January 30, 2009
Last Verified: January 2009
Keywords provided by Solvay Pharmaceuticals:
comparator trial
hypertension
diabetes
blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Eprosartan
Antihypertensive Agents
Angiotensin II Type 2 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action